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Abstract 
Background: Reactivation of latent viruses such as human cytomegalovirus (HCMV) after allogeneic hematopoietic 
stem cell transplantation (HSCT) results in high morbidity and mortality. Effective immunization against HCMV shortly 
after allo-HSCT is an unmet clinical need due to delayed adaptive T cell development. Donor-derived dendritic cells 
(DCs) have a critical participation in stimulation of naïve T cells and immune reconstitution, and therefore adoptive DC 
therapy could be used to protect patients after HSCT. However, previous methods for ex vivo generation of adoptive 
donor-derived DCs were complex and inconsistent, particularly regarding cell viability and potency after thawing. 
We have previously demonstrated in humanized mouse models of HSCT the proof-of-concept of a novel modality of 
lentivirus-induced DCs (“SmyleDCpp65”) that accelerated antigen-specific T cell development.
Methods: Here we demonstrate the feasibility of good manufacturing practices (GMP) for production of donor-
derived DCs consisting of monocytes from peripheral blood transduced with an integrase-defective lentiviral vector 
(IDLV, co-expressing GM-CSF, IFN-α and the cytomegalovirus antigen pp65) that were cryopreserved and thawed.
Results: Upscaling and standardized production of one lot of IDLV and three lots of SmyleDCpp65 under GMP-com-
pliant conditions were feasible. Analytical parameters for quality control of SmyleDCpp65 identity after thawing and 
potency after culture were defined. Cell recovery, uniformity, efficacy of gene transfer, purity and viability were high 
and consistent. SmyleDCpp65 showed only residual and polyclonal IDLV integration, unbiased to proto-oncogenic 
hot-spots. Stimulation of autologous T cells by GMP-grade SmyleDCpp65 was validated.
Conclusion: These results underscore further developments of this individualized donor-derived cell vaccine to 
accelerate immune reconstitution against HCMV after HSCT in clinical trials.
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Zusammenfassung 
Hintergrund: Die Reaktivierung latenter Viren wie das humane Cytomegalovirus (HCMV) führt zu einer hohen Mor-
bidität und Mortalität nach allogener Stammzelltransplantation (allo-HSZT). Aufgrund verzögerter T-Zell-Entwicklung 
nach allo-HSZT ist eine wirksame Immunisierung der Patienten gegen HCMV von großer klinischer Bedeutung. Dabei 
spielt die Immunrekonstitution Dendritischer Zellen (DCs) eine wichtige Rolle. Frühere Verfahren zur ex vivo Gener-
ierung von DCs zur klinischen Anwendung sind komplex und wenig reproduzierbar, insbesondere im Hinblick auf 
die Vitalität und Potenz der Zellen nach der Kryopreservierung. In früheren Arbeiten konnten wir in humanisierten 
Stammzelltransplantations-Maus-Modellen eine neue Methode mittels Lentivirus-induzierten DCs (“SmyleDCpp65”) 
vorstellen, die zu einer beschleunigten Entwicklung antigen-spezifischer T-Zellen führt.
Verfahren: In der vorliegenden Arbeit zeigen wir die Möglichkeit, Monozyten mit einem Integrase-defekten lentivi-
ralen Vektor (IDLV) unter guter Herstellungspraxis (GMP) zu transduzieren zur Ko-expression von GM-CSF, IFN-α und 
pp65 Zytomegalovirus Antigen. Nach Transduktion wurden die Zellen kryokonserviert.
Ergebnisse: Die standardisierte Produktion des IDLVs und die Herstellung von SmyleDCpp65 (n=3) unter GMP-kon-
formen Bedingungen konnte demonstriert werden. Analytische Parameter zur Qualitätskontrolle der SmyleDCpp65 
Identität nach dem Auftauen und Potenz nach der Kultivierung wurden definiert. Zellgewinnung, Uniformität der Zel-
len, Effizienz des Gentransfers, Reinheit und Vitalität waren hoch und konsistent. SmyleDCpp65 Zellen zeigten geringe 
IDLV Integrationen im Genom und ein polyklonales Integrationsmuster ohne Präferenz zu Protoonkogenen. Letztend-
lich wurde ein Verfahren zur Stimulation autologer T-Zellen durch GMP-SmyleDCpp65 validiert.
Fazit: Die weitere Entwicklung dieser individuellen Zellvakzine für klinische Studien ist von hoher Relevanz, um die 
Immunrekonstitution gegen Zytomegalovirus nach allo-HSZT zu beschleunigen.
Background
Allogeneic hematopoietic stem cell transplantation (allo-
HSCT) is a routine standard of care procedure for pre-
venting relapse in patients with hematologic malignancies 
such as acute myeloid leukemia (AML) [1]. Cytoreduc-
tive conditioning regimens, T cell depletion and immune 
suppressive therapies used in the context of allo-HSCT 
elicit a delay in adaptive immunity, predisposing patients 
to infections. Regeneration of naïve and memory T cells 
after allo-HSCT requires the de novo production of naïve 
T cells in thymus and memory T cells in the periphery 
[2]. Among infections and reactivations after allo-HSCT, 
human cytomegalovirus (HCMV) is a major challenge 
for clinicians and patients due to high morbidity, mortal-
ity and significant costs for management with antiviral 
drugs or adaptive T cell therapy [3, 4]. No effective clini-
cal vaccines are currently approved against HCMV in 
the allo-HSCT setting [5]. At the time when the patients 
need immunological protection the most, they are still 
severely lymphopenic, immune compromised or immune 
suppressed and the state-of-the-art vaccines do not pro-
vide effective protective immunity. Third party adop-
tive T cells require complex manufacturing and are in 
later phase clinical trials (NCT01077908), but have not 
received approval or pricing authorization by the FDA or 
EMA yet. Thus, simple innovative, relatively inexpensive 
and individualized cell therapy approaches are warranted 
to cover this unmet clinical need.
Dendritic cells (DCs) are potent regulators of immunity 
capable of priming naïve lymphocytes for long-lasting 
and highly efficient adaptive immune responses. One 
special hallmark the immune surveillance by DCs is their 
migratory behavior from tissues to lymph nodes (LN), 
where they utilize the optimized cyto-architecture in ger-
minal centers to encounter and stimulate naïve T and B 
cells. T cell receptors (TCRs) are stimulated by specific 
antigenic epitopes presented by the major histocompat-
ibility complex (MHC) highly expressed on DCs [6]. DCs 
have different mechanisms to internalize and process 
antigens, and a long-lasting exposure of naïve T and B 
cells to antigens processed and presented by DCs in LN 
can maximize the immunologic synapse for selection of 
high-affinity TCRs and B cell receptors (BCRs) [7].
Even up to 1 year after allo-HSCT, DC levels are usu-
ally abnormal and patients with faster DC recovery show 
lower mortality [8]. Incidentally, HCMV can further 
hamper immune reconstitution by interfering with den-
dritic cell differentiation and function [9]. Thus, the use 
of adoptive ex vivo “conventional” monocyte-derived DC 
has been explored in a few phase I/II studies to protect 
or treat HSCT recipients against HCMV [10, 11]. In one 
study, patients immunized with peptide-loaded donor-
derived conventional DCs showed a proof-of-concept 
clinical benefit with induction of HCMV-specific cyto-
toxic T lymphocytes (CTLs) in 30% of patients [11]. 
Notably, this pilot clinical trial demonstrated no immu-
notoxic or detrimental effects of the DC vaccination in 
exacerbating Graft-versus-host disease (GVHD). How-
ever, further clinical developments were hampered due 
to the complex, costly and inconsistent production of 
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conventional DCs under good manufacturing practice 
(GMP) [12]. Production of conventional DCs requires 
several days of GMP culture, is difficult for large-scale 
production and faces difficulties towards good automated 
manufacturing practice (GAMP). Finally, the low viability 
and migratory properties of clinical-grade conventional 
DC after administration into patients is considered a 
major concern for their sub-optimal bio-distribution to 
LN and clinical potency [6].
During the past decade, lentiviral vectors (LV) have 
been intensively explored to enable persistent antigen 
expression in DCs to enhance immunization [13–15]. 
Integrase-defective lentiviral vectors (IDLV), which can 
potentially lower the genotoxicity risks mediated by viral 
insertional mutagenesis, are currently being tested experi-
mentally as recombinant viral vaccines against infections, 
cancer and parasites [16–19]. We have previously shown 
in a series of studies that monocytes can be programmed 
with lentiviral vectors to self-differentiate autonomously 
into highly viable and activated DCs [20–23]. We have 
employed IDLV for co-expression of granulocyte-mac-
rophage colony stimulating factor (GM-CSF), interferon 
(IFN)-α, and the immune dominant HCMV pp65 tegu-
ment antigen [20, 22]. This combination of transgenes 
enabled monocytes to autonomously become Self-differ-
entiated myeloid-derived lentivirus-induced DC express-
ing pp65 (SmyleDCpp65) after a single overnight ex vivo 
gene transfer [20, 22]. Prime/boost immunizations with 
SmyleDCpp65 after transplantation of immune deficient 
NOD.Rag1−/−.IL2rγ−/− (NRG) mice with human CD34+ 
stem cells resulted in remarkable acceleration of de novo 
immune reconstitution, LN regeneration, improved 
expansion of mature T and B cells and pp65-specific 
human T and antibody responses [22, 23].
Here, we pre-clinically showed in a simple and short fully 
GMP-compliant production scheme that SmyleDCpp65 
cryopreservation and thawing were feasible and did not 
negatively affect characteristics and function of the cells. 
In addition, state-of-the-art analytical methods for QC 
and batch release, insertional mutagenesis assessment 
risk and potency characterization were established.
Methods
Cell lines
The HEK-293 (human embryonic kidney-293) cell line 
encoding the simian virus 40 (SV40) large T antigen 
(heretofore, 293T cells) was used for the production 
and characterization of lentiviral vectors (both research 
grade and GMP grade). A master cell bank (MCB) of 
293T cells was established at EUFETS GmbH (Idar-
Oberstein, Germany). Two randomly picked 293T MCB 
vials were tested for sterility, endotoxins, mycoplasma 
and adventitious viruses in full compliance with the 
GMP requirements of the local regulatory authorities. 
These safety tests have shown that the MCB was devoid 
of bovine, porcine and human viruses. HT1080 (human 
fibrosarcoma cell line) was used for titration of the len-
tivirus produced with GMP grade materials. 293T cells 
and HT1080 cells were cultured at 37°C and 5% CO2 in 
Dulbecco’s modified Eagle’s medium (DMEM, Invitro-
gen, Darmstadt, Germany) supplemented with 10% fetal 
bovine serum (FBS, HyClone, Fischer Scientific GmbH, 
Bonn, Germany). The reference K562 cells co-expressing 
HLA-A02*01 and pp65 were cultured in RPMI supple-
mented with 10% FBS, 1% penicillin/streptomycin and 
1 mg/mL geneticin (Biochrom AG, Berlin, Germany).
Lentiviral vectors and plasmids
ICLV-pp65 used for control experiments was produced 
as previously described [21]. IDLV-G2α2pp65 was pro-
duced by transient transfection of four plasmids con-
taining the transfer plasmid RRL-CMV-G2α2pp65, the 
packaging plasmid pCDNA3.g/pD64V.4xCTE encod-
ing the D64V mutation in the integrase gene, the pack-
aging plasmid expressing Rev and the pMDG plasmids 
encoding for the vesicular stomatitis virus G glycoprotein 
(VSV-G) as described [20]. For GMP production of the 
virus, all plasmids were fully sequenced and produced 
by PlasmidFactory GmbH (Bielefeld, Germany) as ccc-
supercoiled Grade plasmids (enzyme free and devoid of 
bovine derived material and certified for purity). IDLV-
G2α2pp65 was produced under GMP conditions follow-
ing standard operation procedure (SOP) established at 
EUFETS GmbH. On day 0, 40 stack cell factories were 
seeded with 293T cells and transfected with qPEI (Poly-
ethylenimine) transfection reagent. 24  h after transfec-
tion, medium change and Benzonase treatment were 
performed. Supernatant containing virus was harvested 
48  h after transfection (total volume 2,500  mL), filtered 
through 0.8 and 0.45 µm filters and purified by chroma-
tography (CEX). Tangential flow filtration and dialysis 
was performed and the viral supernatant was concen-
trated approximately 33-fold (to 74  mL). The purified 
virus was filtered with 0.45 and 0.2  µm filters, the final 
product was aliquoted as 1 mL/vial and stored at −80°C.
Titration of IDLV‑G2α2pp65 by p24 analyses
Physical titers of the vectors produced (Research grade 
and GMP grade) were determined by quantifying the p24 
HIV-I core protein by ELISA (QuickTiter™ HIV Lentivi-
rus Quantitation Kit, BioCat, Heidelberg, Germany).
Titration of the vector and analyses of vector copy 
numbers in monocytes by RT‑q‑PCR
For virus titration, HT1080 cells were transduced and 
genomic DNA was extracted from using the QiaAmp 
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DNA blood mini kit (Qiagen, Hilden, Germany) accord-
ing to the manufacturer’s instructions. For analyses of 
IDLV copy numbers in transduced monocytes, total 
DNA (tDNA) was extracted using the Epicenter Mas-
terpure DNA isolation kit (Madison, WI, USA), with 
adaptations [24]. Cells lysates with incubated with pro-
teinase K treatment, (45 min at 65°C), RNase A treatment 
(10  µg, 37°C for 30  min) and proteins removed by pre-
cipitation. The tDNA was precipitated from supernatants 
with isopropanol and solubilized in 85  µL of tris-buffer 
according to the manufacturer’s instructions. IDLV copy 
numbers were determined by real-time PCR as previ-
ously described [22, 25]. Shortly, 2 µL containing 100 ng 
of genomic DNA were added to 13 µL of RT-q-PCR mix 
[containing 7.5 µL of SYBRTaq mix with 1 µL of wPRE/
PTB2 primer mix (wPRE forward: 5′-GAGGAGTTG 
TGGCCCGTTGT, wPRE reverse: 5′-TGACAGGTGG 
TGGCAATGCC or PTBP2 (polypyrimidine tract bind-
ing protein 2; PTBP2 forward: 5′-TCTCCATTCC 
CTATGTTCATGC, PTBP2 reverse: 5′-GTTCCCGCAG 
AATGGTGAGGTG) and 4.5  µL PCR grade, nuclease 
free water]. All samples were analyzed with StepOne-
Plus™ Real time PCR system (Applied Biosystems, Life 
Technologies, Darmstadt, Germany). The cycling condi-
tions were 10 min at 95°C, 40 cycles of 15 s at 95°C, 20 s 
at 56°C and 30 s at 65°C. Results were quantified by mak-
ing use of primer pair-specific real-time PCR efficiencies 
and by comparing sample CT values to a standard curve 
generated with the plasmid vector (pCR4-TOPO) con-
taining the wPRE and PTB2 sequences. Data was ana-
lyzed by StepOnePlus™ software (Applied Biosystems).
Research grade (RG) SmyleDCpp65 generation
Leukapheresis of non-mobilized HCMV-seropositive 
and HLA-A02*01 positive adult healthy donors was per-
formed in accordance with study protocols approved by 
Hannover Medical School Ethics Review Board. Periph-
eral blood mononuclear cells (PBMNCs) were purified 
by sediment centrifugation (Ficol, Biochrome AG) and 
cryopreserved. CD14+ cells were selected using CD14 
immunomagnetic microbeads (MACS, Miltenyi Biotec, 
Bergisch Gladbach, Germany) and processed as pre-
viously described [20, 22]. In short, CD14+ cells were 
pre-conditioned with hGM-CSF and hIL-4 (50  ng/mL 
each, CellGenix, Freiburg im Breisgau, Germany) for 
8  h followed by transduction. IDLV-G2α (a bicistronic 
vector expressing GM-CSF and IFN-α, but no antigen) 
was used to generate “empty” SmyleDCs, while IDLV-
G2α2pp65 (a tricistronic vector expressing GM-CSF, 
IFN-α and pp65) was used to generate SmyleDCpp65. 
The design and validation of these vectors were described 
previously [20, 22, 23]. For production of research grade 
SmyleDC or SmyleDCpp65, 2.5  μg/mL p24 equivalent 
of the respective vector were used to transduce 5 × 106 
monocytes at MOI of 5 in the presence of 5 μg/mL pro-
tamine sulfate (Valeant, Eschborn, Germany) for 16  h. 
After transduction, cells were washed twice with Cell-
Gro medium (CellGenix). Cells were cryopreserved in 
freezing medium containing 15.5% human albumin, 
10% DMSO and 5%Glucose. Conventional IFN-α DCs 
were generated from monocytes by supplementing the 
medium with hGM-CSF and hIFN-α every 3 days.
SmyleDCpp65 production with GMP compliant methods
Leukapheresis of non-mobilized HCMV sero-positive 
HLA-A02*01 and/or HLA-B07*02 healthy adult volun-
teers was performed with a COBE® Spectra apheresis 
system. PBMCs were used fresh for selection of CD14+ 
monocytes with a GMP-compliant CliniMACS immu-
nomagnetic separation system (Miltenyi Biotec). Quan-
titative and qualitative analyses of the selected CD14+ 
fraction and flow through were performed by flow 
cytometry. From the enriched CD14+ fraction, 1.5 × 108 
cells were resuspended in 25  mL of serum free Cell-
Gro DC medium (CellGenix) and seeded in a 100  mL 
bag (CellGenix). Cells were preconditioned with 25  mL 
of medium containing hGM-CSF and hIL-4 cytokines 
(50  ng/mL each, CellGenix) for 8  h. Cells were trans-
duced with 7.5 ×  108 infective particles (multiplicity of 
infection of 5) in 50  mL medium containing Protamine 
sulphate (5 µg/mL). The bag was incubated at 37°C and 
5% CO2 for 16 h. Next day, cells were washed three times 
with CellGro medium. After washing, cell number and 
viability was determined. Transduced cells were cryopre-
served in aliquots of 2 × 106 cell/mL/vial. Surplus, non-
transduced monocytes were cryopreserved in aliquots of 
2 × 106 cell/mL/vial and 50 × 106 cell/mL/vial and were 
used as controls for the characterization experiments. 
Sterility tests were performed with the “Bactec” system 
(BD Biosciences, Heidelberg, Germany). Three independ-
ent production batches were prepared with three inde-
pendent leukaphereses obtained from three independent 
healthy adult volunteers.
Analyses of thawed GMP grade SmyleDCpp65 by flow 
cytometry analyses
Three independent cryopreserved vials (2 × 106 cell/mL/
vial) of monocytes transduced with IDLV-G2α2pp65 in 
each production batch were analyzed directly at thaw 
(AT), or cultured in CellGro for 5 or 7  days at a con-
centration of 1  ×  106  cells/mL. Surface marker expres-
sion was analyzed by flow cytometry using the following 
monoclonal Ab conjugated with fluorochromes: Krome 
Orange-CD45 (clone J.33), APC750-CD14 (clone 
RMO52), PC7-CD11c (clone BU15), PE-CD86 (clone 
HA5.2B7), Pacific Blue-HLA-DR (clone Immu-357; all 
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from Beckman Coulter, Krefeld, Germany), and APC-
CD80 (clone 2D10; Miltenyi Biotec). Residual cell analy-
ses were performed with the following Ab: APC700-CD3/
CD19 (T and B cells; clones: UCHT1 and J3-119 respec-
tively) and PC5.5-CD56 (NK cells; clone: N901 (HLDA6); 
all from Beckman Coulter). After staining and prior 
to acquisition, Flow-Count™ Fluorospheres (Beckman 
Coulter) were added to the cells to determine the abso-
lute cell counts and to control the flow rate. Expression 
of pp65 was determined by intracellular staining and flow 
cytometry. Cells were stained with the following mono-
clonal antibodies Ab: Krome Orange-CD45 (clone J.33), 
Pacific Blue-CD14 (clone RMO52), PC7-CD11c (clone 
BU15), PE-CD86 (clone HA5.2B7), ECD-HLADR (clone 
Immu-357), and PC5.5-CD56 (clone N901 (HLDA6); 
all from Beckman Coulter). After surface staining, cells 
were washed and permeabilized with BD cytofix/cytop-
erm solution (BD Biosciences). After permeabilization, 
cells were incubated with FITC-conjugated mAB against 
HCMV-pp65 (clone: I1010D; Thermo Scientific, Ger-
many) in a 1:20 dilution with BD perm/wash solution. 
Non-transduced monocytes are used as negative con-
trols and conventional IFN-α DCs were used as positive 
controls. Acquisitions and analyses were performed by 
Navios™ Flow Cytometer and Navios™ analysis software 
(Beckman Coulter).
Analyses of cytokines and transgene expression
SmyleDCpp65 produced under GMP-like conditions 
secreted several endogenous cytokines. We analyzed 
and quantified the levels of a set of commonly highly 
expressed cytokines in culture supernatants (GM-CSF, 
IFN-α, MCP1 and IL-8) by bead array luminex based kit 
according to the manufacturer’s protocol (Milliplex Mili-
pore, MA, USA).
Integration analyses by NGS
Integration analyses were performed by using LAM-
PCR to identify the lentiviral vector-flanking genomic 
sequences as described [26]. Briefly, tDNA was extracted 
from the samples and two 50-cycle linear PCR amplifi-
cation steps were carried out using biotinylated primers 
hybridizing to the 3-prime region of the long terminal 
repeats (LTR) of the vector. The biotinylated PCR-prod-
ucts were further captured with paramagnetic beads 
followed by second strand DNA synthesis, restriction 
digestion and ligation of a cohesive double-stranded 
linker sequence carrying a molecular barcode of 12  nt. 
Two nested PCR were then performed with linker and 
vector specific primers each complementary to one of 
the known ends of the target DNA. In 5′–3′ orienta-
tion, LAM-PCR products contained a LTR sequence, a 
flanking human genomic sequence and a linker cassette 
(LC) sequence. LAM-PCR amplicons were further pre-
pared for MiSeq sequencing (Illumina, San Diego, CA, 
USA). Therefore, an additional PCR with special fusion-
primers carrying MiSeq specific sequencing adaptors 
was performed. DNA barcoding was used to allow par-
allel sequencing of multiple samples in a single sequenc-
ing run. Libraries were mixed with an ϕX bacteriophage 
genome library to introduce diversity and optimize the 
sequencing run performance and sequenced using the 
Illumina MiSeq v2 Reagent Kit. The pair-end runs were 
initiated for Illunima’s sequencing by synthesis technol-
ogy, including clustering, paired-end preparation, bar-
code sequencing and analysis. After completion of the 
run, base calling was performed on data, sequences were 
de-multiplexed and ϕX reads were filtered. Next genera-
tion sequencing (NGS) data processing dealt with the 
management of high-throughput data from Roche 454/
Illumina MiSeq sequencing platforms and comprise two 
main goals: (1) data quality inspection and analysis, in 
which lentiviral vector sequences and other contami-
nants were trimmed; (2) integration site identification, in 
which all valid sequence reads are aligned to the genome 
of reference and valid ISs were retrieved.
Characterization of SmyleDCpp65 potency 
after stimulation of T cells in vitro
The potency assays were based on activation of autolo-
gous T cells with SmyleDCpp65, which were produced 
with monocytes after CliniMACS selection. GMP grade-
SmyleDCpp65 were compared with research grade (RG) 
SmyleDCpp65 and SmyleDC produced with monocytes 
from the same donor, but which were produced with 
IDLVs produced in the laboratory. Autologous CD3+ 
T cells from each of the three GMP-grade batches were 
isolated from the CD14neg fraction (MACS positive selec-
tion, Miltenyi Biotec). CD3+ T cells were co-cultured 
with RG-SmyleDC, RG-SmyleDCpp65 or GMP-grade 
SmyleDCpp65 at a ratio of 10–1. Non-stimulated CD3+ 
T cells were used as negative control. CD3+ T cells stim-
ulated for 16  h with 10  µg/mL PepTivator CMV-pp65 
overlapping peptide pool (Miltenyi Biotec) were used as 
reference controls for the IFN-γ intracellular detection 
assay. Protein transport inhibitor cocktail (eBioscience, 
Frankfurt, Germany) was added to the cells 1  h after 
stimulation. After 16  h, T cells were harvested, stained 
with APC-conjugated anti-human CD3, Pacific Blue-
conjugated anti-human CD4 and PECy7-conjugated anti-
human CD8 antibodies. After fixation/permeabilization 
with Cyofix/perm (BD Biosciences) for 20 min at 4°C and 
washing, anti-human PE-IFNγ (eBioscience) was used 
for staining for 30 min. The cells were acquired by flow 
cytometry using LSRII (BD Biosciences) and analyzed by 
Flowjo® software (Treestar Inc., Ashland, OR, USA).
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Statistical analysis
Parametric (t test) and non-parametric Mann–Whitney 
U test were used for determining statistical significance. 
All tests were two-sided, and p < 0.05 was considered sig-
nificant. Data was analyzed with GraphPad Prism 5 soft-
ware (GraphPad Software, Inc., CA, USA).
Results and discussion
Feasibility of IDLV‑G2α2pp65 production under GMP‑like 
compliant conditions
We have previously demonstrated and validated a tricis-
tronic vector IDLV-G2α2pp65 co-expressing simultane-
ously GM-CSF, IFN-α and pp65 (Additional file 1: Figure 
S1A) for generation of SmyleDCpp65 [23]. Advancing 
towards clinical grade SmyleDCpp65 for clinical trials, 
we evaluated the feasibility of vector production and cell 
generation under GMP compliant conditions. In col-
laboration with a contract manufacturing organization 
(CMO, EUFETS GmbH), we validated upstream and 
downstream processes and established standard-operat-
ing-protocols (SOPs) for production of the vector IDLV-
G2α2pp65 by transfection of 293T cells. High purity ccc 
plasmids consisting the transfer vector (LV-G2α2pp65), 
the gag/pol vector harboring a D64V mutation (pcD-
NA3g/pD64V.4xCTE), the vector containing codon 
optimized REV (pRSV-REV), and the envelope vector 
expressing VSV-G (pMD.G) were used for transfection 
in 40 stack cell factories (Figure 1a). After transfection, 
viral supernatant was harvested and subjected to down-
stream purification (benzonase treatment, filtration, 
chromatographic purification, tangential flow filtration, 
sterile filtration, filling and storage). At each step of the 
purification process, a QC step was added to determine 
the recovery and yield of IDLV (Figure  1a). Infectious 
titer of IDLV-G2α2pp65 was determined by RT-q-PCR 
and the physical titer by quantifying the HIV-I core pro-
tein p24. Starting with 2 ×  106 infectious particles/mL 
(ip/mL; 2  L volume) after CEX purification, final prod-
uct was concentrated by 33-fold in relation to the start-
ing volume with a final titer of (from 2,500 to 74  mL; 
Figure  1a). The filtration and concentration steps did 
not alter the infective titer of IDLV. The final product 
showed a titer of 5.7  ×  107  ip/mL in a total of 74  mL 
(4.2 × 109 infectious particles) (Figure 1b). On the other 
hand, physical p24 titer of IDLV-G2α2pp65 revealed 
major reduction after CEX purification, filtration and 
dialysis steps (Figure  1c), which was probably due to 
removal of empty particles and cell debris containing 
p24 during the purification process. Overall, GMP-grade 
IDLV-G2α2pp65 production and recovery demonstrated 
that IDLV production was not fundamentally different 
from ICLV production methods established by the same 
CMO.
Feasibility of SmyleDCpp65 generation 
and cryopreservation under GMP‑like compliant 
conditions
Since cryopreservation of SmyleDCpp65 could facilitate 
the production logistics, storage and performance of 
quality control analyses, we performed preliminary tests 
to evaluate the effects of cryopreservation immediately 
after IDLV transduction (representative example Addi-
tional file 1: Figure S1B-F). After thaw (AT), transduced 
cells were highly viable 7AADneg and pure CD14+ mono-
cytes containing detectable IDLV copies. After culture 
for 7  days, SmyleDCpp65 maintained IDLV copies and 
the persistent gene transfer was associated with expres-
sion of the pp65 antigen. After culture, SmyleDCpp65 
were still highly viable, down-regulated the expression 
of monocytic marker CD14+, up-regulated the expres-
sion of the DC marker CD11c and co-expressed the rel-
evant molecules HLA-DR/CD86 and HLA-DR/CD80. 
Therefore, under good research practice, cryopreserva-
tion was not detrimental to recovery of self-differentiated 
SmyleDCpp65 after thawing.
Therefore, we proceeded with upscaling the produc-
tion of cryopreserved SmyleDCpp65 with SOPs using 
the vector generated under GMP-like conditions. The 
standardized production was validated in three inde-
pendent runs. Ex vivo monocyte manipulation starting 
with leukapheresis at the clinical center and proceeding 
with transportation under controlled conditions to the 
CMO for CD14+ isolation, cytokine preconditioning, 
transduction, wash and cryopreservation could be fully 
achieved in only 3 days (Figure 2a). In process QC steps 
were included after each step in the production pro-
cess to assess the cell viability and recovery (Figure 2a). 
In order to assess the purity, viability and recovery of 
monocytes from the leukapheresis until thaw, in process 
QC steps were added after each step in the production 
process. Three independent CD14+ CliniMACS® enrich-
ments were performed with leukapheresis obtained from 
donors, resulting in >80% viable CD14+ purity (Table 1). 
A range of 0.47–1.00 × 109 CD14+ cells were recovered 
from 1.47–2.29  ×  109 PBMNCs (Figure  2b). 1.5  ×  108 
CD14+ monocytes were used in transductions with 
GMP-grade IDLV-G2α2pp65 at an MOI of 5 (7.5 ×  108 
infectious particles). After transduction and washing, 
0.60–1.23 ×  108 viable monocytes were recovered (Fig-
ure  2b). SmyleDCpp65 were cryopreserved as 2  ×  106 
cells in 1 mL per vial as the final cell product. A fraction 
of the CD14+ cells that were not transduced were equally 
cryopreserved at 2 × 106 cells per mL per vial and were 
used as negative controls for the QC analyses. Sterility 
tests were negative for bacterial and fungal contamina-
tion (data not shown). After cryopreservation, samples 
were transported to our clinical center under controlled 
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conditions for further QC and characterization analyses. 
At independent time points, three vials from each of the 
three SmyleDCpp65 production batches were thawed 
and characterized for sterility, viability, identity and 
purity. At thaw (AT), a range of 0.60–1.73 × 106 cells cor-
responding to 30.0–86.5% of the cryopreserved cells were 
Figure 1 Standardized production of IDLV-G2α2pp65 under GMP compliant conditions up-scaling, recovery and titration. a Schematic representa-
tion of pilot batch of the lentiviral vector production performed under GMP compliant conditions. In process QC analyses are shown. b Infective 
titer of IDLV samples collected during different steps of GMP-compliant production. Indicator cells (HT1080) were transduced and the number of 
vector copies in genomic DNA was determined by RT-q-PCR. c Quantification of IDLV physical titer as p24 equivalent by ELISA.
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recovered (Figure 2c). Cell counts performed at the CMO 
demonstrated that 30% of the cells seeded AT maintained 
viable after ex vivo culture for 5–7 days (Figure 2c). 
The most relevant criteria to ensure quality of the cell 
product after filling, cryopreservation and thawing are 
purity and viability. Thus, standardized quality control 
analyses to define these parameters were performed in 
collaboration with a GMP development unit in our insti-
tution. After thawing, SmyleDCpp65 showed undiffer-
entiated monocyte morphology and high viability (>90% 
7AAD), expressed monocyte markers (>90% CD45+ and 
CD14+) and showed low frequency of residual T and B 
cells (<1% CD45+/CD19+/CD3+) (Figure  3a–c). Unex-
pectedly, as we intended to evaluate the frequency of 
b Absolute viable CD14+ cells c Recovery relative to cryopreservation
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Residual cells (CD19, CD3, CD56-
FACS)
IDLV total copies per cell (tDNA-q-
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Figure 2 Standardized production of SmyleDCpp65 under GMP compliant conditions. a Schematic flow diagram representing the production of a 
pilot batch of SmyleDCpp65 generation under GMP-like conditions and analyses. CD14+ monocyte selections from three independent leukapher-
esis were performed by CliniMACS. 1.5 × 108 monocytes were transduced in bags with 7.5 × 108 infectious particles (MOI of 5). Transduced mono-
cytes were washed and cryopreserved. Analyses on day 0 after thaw for QC and batch release and on days 5 and/or 7 for identity and pharm-tox are 
shown. b CD14+ cell recovery as viable cell numbers after each step of production process and AT (extrapolated). c Percentage recovery of viable 
cells AT, days 5 and 7 after culture in medium without exogenous addition of cytokines (3 independent runs; n = 3 for each run).
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residual natural killer cells with the CD56 marker, we 
observed a consistent population (8%) of CD56+ cells, 
which may relate to the recently reported CD56+ IFN-
α-induced dendritic cells shown to efficiently stimulate 
autologous Vγ9γδT cells [27].
As the biological activity of SmyleDCpp65 depends 
on the successful transduction, detection of IDLV cop-
ies is a primary criterion for QC of the process. For the 
first batch of transduced monocytes (“GMP1”), there 
was a technical problem with the liquid nitrogen storage 
of samples at the CMO site. Thus, some of the samples 
of GMP1 were lost and could not be further analyzed 
regarding IDLV integration. AT, tDNA was isolated for 
GMP2 and GMP3 batches. Non-transduced monocytes 
obtained from the same donors were used as baseline 
control. IDLV copies could be detected in the GMP batch 
2 (0.66 copies per cell, 11× above assay baseline) and in 
the GMP batch 3 (1.31 copies per cell, 6× above assay 
baseline) (Figure  3d). All together, these results dem-
onstrated a robust and consistent 3-day manufacturing 
method for generation of cryopreserved SmyleDCpp65 
under GMP.
c  Percentage viability and purity (n=3,  in triplicate)
b  Viability, identity and purity analyses after thaw
a  Phase microscopy after thaw
d  IDLV copies/ cell 
GMP1 GMP2 GMP3
Figure 3 Characterization of transduced CD14+ monocytes after thaw (AT). a Phase microscopy of transduced CD14+ cells AT showing viable 
monocytes. b Representative example of flow cytometry gating for QC and batch release criteria, showing high viability, purity and expected 
monocyte characteristics of the product. c Overall viability (7AADneg), purity (CD45+CD14+) and quantification of residual cells (T cells and B cells: 
CD45+ CD3+/CD19+ and NK cells: CD45+CD56+) for the three SmyleDCpp65 production runs (GMP1: n = 2; GMP2: n = 3; GMP3: n = 3 independ-
ent analyses). d Detection of IDLV copies in tDNA extracted from transduced SmyleDCpp65 and cognate non-transduced monocytes (both groups 
AT) by RT-q-PCR. PCR signal in transduced monocytes compared with baseline is indicated. Bar graphs indicate mean and the error bars indicate 
mean ± SEM.
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Characterization of SmyleDCpp65 after in vitro culture
Analytical validation methods were established to 
demonstrate parameters of the cells after thawing and 
in  vitro culture such as morphology, high viability, self-
differentiation into an activated DC phenotype, expres-
sion of pp65 and cytokines. Cells were thawed, seeded 
at 106 cells/mL, and re-analyzed immediately after thaw 
(day 0) or after 5 and 7 days of culture. Three independ-
ent cryopreserved SmyleDCpp65 vials from each produc-
tion batch were thawed and analyzed and corresponding 
triplicates of freshly thawed monocytes and conventional 
monocyte-derived DCs from the same donor were used 
as control parameters for the flow cytometry analyses. 
While non-transduced monocytes showed clear viability 
loss after 3 days of culture in absence of added cytokines, 
 SmyleDCpp65 maintained viable and progressively 
showed morphologic changes towards DC differentia-
tion from days 3–7 of culture (Figure 4a). Two panels of 
antibodies were developed for flow cytometry characteri-
zation of the activation status of SmyleDCpp65 (Panel I; 
viable), and to detect the expression of the pp65 antigen 
in DCs (Panel II; permeabilized) (Figure  4b; Table  2). 
For the activated DC panel, CD45+ hematopoietic cells 
were stained for viability (7AAD), the monocyte marker 
(CD14, down-regulated) and DC markers (CD11c, up-
regulated). Activated SmyleDCpp65 were identified 
as 7AADneg, CD45+, CD14neg, CD11chigh, HLA-DR+, 
CD86+ or 7AADneg, CD45+, CD14neg, CD11chigh, HLA-
DR+, CD80+ (Figures 4c, d and 5a). Hence, SmyleDCpp65 
cultured for 5 and 7 days, down-regulated CD14 expres-
sion (AT: >95%; day 5: 4%; day 7: <1%), expressed high 
levels of DC markers CD11c (12.2% AT; day 5: 94%; day 
7: 97%; Figure  4c), co-expressed HLA-DR/CD86 (36% 
AT; day 5: 65.58%; day 7: 75.45%; Figure  4d) and highly 
expressed HLA-DR/CD80 (16.6% AT; day 5: 88.25%; 
day 7: 91.71%; Figure  5a). Although both CD86 (B7-2) 
and CD80 (B7-1) are key co-stimulatory molecules both 
providing signaling to T cells through binding to the co-
stimulatory receptor CD28 or the co-inhibitory receptor 
CTLA-4, expression of CD86 is stable and can be found 
in immature DCs, whereas CD80 expression is upregu-
lated and a hallmark of active DCs [28]. Residual cells 
were identified by gating on viable cells (7AADneg) and 
stained for CD3, CD19 and CD56. For qualitative analy-
ses of pp65 expression in DCs, non-transduced mono-
cytes were used as for setting up the negative controls 
gates, and freshly thawed K562/pp65 were used as posi-
tive controls for pp65 expression (Additional file 2: Figure 
S2). Cells were stained with surface markers, permeabi-
lized and stained for pp65. Frequency of pp65+ express-
ing DCs was represented as CD45+, CD14neg, CD11chigh 
and pp65+ (AT: 4.28%; day 5: 16.4%; day 7: 33.71%; Fig-
ure 5b). Thus, expression of pp65 continuously increased 
during culture. Bead array analyses of SmyleDCpp65 
cell culture supernatants demonstrated only baseline 
levels of secreted transgenic cytokines AT, whereas 
detectable levels of GM-CSF (day 5: 7.26 and day 7: 
7.02  pg/106  cells/mL) and IFN-α (day 5: 32.93 and day 
7: 33.25  pg/106  cells/mL) could be measured in the cell 
supernatant only after 5 or 7 days of culture (Figure 5c). 
In addition, high levels (>104 pg/106 cells/mL) of endog-
enous up-regulated monocyte chemotactic protein-I 
(MCP-I) and IL-8 were detectable in cell culture superna-
tants harvested on days 5 and 7 (Figure  5d). MCP-I and 
IL-8 are chemokines and we have previously demonstrated 
dramatic up-regulation of these cytokines in lentivirus-
induced DCs [22, 29]. Therefore, analyses of quality control 
by these flow cytometry and luminex  systems provided a 
consistent pattern of the product and confirmed identity 
and immunologic potency of SmyleDCpp65. 
Analyses of IDLV copies and genomic integrations 
in SmyleDCpp65 and polyclonality
Although IDLVs are currently explored in experimental 
animal models to be used as recombinant viral vaccines 
against infections, cancer and parasites [16–18], there is 
still a lack of studies in human preclinical studies correlat-
ing transgene expression, vector copy numbers and pattern 
of residual integration. Due to the potential risk of inser-
tional mutagenesis, this is a serious preclinical requirement 
to be observed. Residual lentiviral integration of IDLV was 
characterized in hepatocytes of mice infused with IDLV, 
demonstrating that the risk was greatly reduced but not 
totally eliminated [30]. At day 7 after culture, we could esti-
mate based on detection of pp65 antigen as a qualitative 
method, that at least 30–40% of the cells produced under 
GMP were transduced (Figure  6a). Analyses of different 
batches of cells by quantitative RT-PCR demonstrated that 
IDLV copy content per cell ranged between 0.5 and 1.2 cop-
ies per cell (Figure 6b). We subsequently compared the LV 
integration pattern observed in day 7 SmyleDCpp65 trans-
duced with vectors produced as research grade (ICLV ver-
sus IDLV) and as GMP grade (GMP-2 and GMP-3). DNA 
was extracted and analyzed by LAM-PCR and NGS and the 
clonal frequencies of the transduced monocytes maintained 
in culture for 7 days was monitored with a high throughput 
IS analysis [26]. The number of total vector sequences that 
could be retrieved for the four groups were in similar orders 
of magnitude (0.5–1.0 × 104 sequences, Figure 6c). How-
ever, the detectable number of unique insertion sequences 
(IS) was much higher for RG-ICLV (>1,000) than RG-IDLV 
(335). Unique IS detectable for GMP2-IDLV and GMP3-
IDLV combined were even lower, in total 99 sequences 
(Figure 6d). This indicated that only residual genomic len-
tiviral integration sites could be observed after IDLV gene 
transfer of monocytes under GMP-compliant conditions. 
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Figure 4 Characterization of SmyleDCpp65 after in vitro culture for 5 or 7 days without exogenous cytokines. a Morphology analyses by phase 
microscopy. SmyleDCpp65 thawed and cultured for 3, 5 or 7 days showing high viability throughout and acquisition of typical DC morphology and 
cell clustering from day 5 onwards. b Methods for flow cytometry analyses for characterization of SmyleDCpp65 identity [Panel I (viable)—DC phe-
notype] and potency [Panel II (permeabilized)—pp65 expression] and representative examples for each GMP batch analyzed. c Average frequency 
of viable DCs (CD14−, 7AAD−, CD45+ CD11cbright cells) for all analyses of GMP batches combined. d Average frequency of activated DCs co-express-
ing HLA-DR/CD86. Data represent the combined data obtained for three independent SmyleDCpp65 production runs, two independent analyses 
for GMP1 and three independent analyses for GMP2 and GMP3 (in total 8 analyses). Bar graphs indicate mean and error bars indicate mean ± SEM. 
*p < 0.05, **p < 0.01, ****p < 0.0001.
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Whereas for the research-grade vectors IDLV integra-
tions were found in all chromosomes and frequencies 
were roughly correlated with chromosome size, interest-
ingly no integrations were found in chromosome 22 for the 
two GMP-grade batches of SmyleDCpp65 (Figure 6d). As 
expected, ICLV integrated sequences were found in higher 
frequency in genes than upstream of the transcription 
start site (TSS) (Figure 6e). Surprisingly, for the RG IDLV 
sample, vector integrations were most frequent up to 5 kb 
upstream of the TTS. In turn, integrations detectable in the 
two GMP SmyleDCpp65 batches show a random distribu-
tion, but mostly in genes (Figure 6e). Although one could 
speculate that IDLV pattern of integration may indeed be 
more random than ICLV in monocytes, we would have to 
compare more samples for further analyses. Nevertheless, 
a relevant information was that IDLV genome integra-
tions in gene loci were random and highly diverse among 
all RG and GMP samples analyzed. The research grade 
vectors showed higher polyclonality, but this may be due 
to the fact that there were more sequences to be analyzed. 
The 10 most frequent identified gene loci among the four 
samples were discordant and did not occur near oncogenes 
(Figure  6f). Tracking of the most common clones based 
on a Common Integration Site (CIS) statistical models 
[31–33] showed that, for RG-IDLV transduction, only one 
integration could be observed as 4th order (4 integrations 
within 100  kb genomic region, one of them in TRIM27), 
four integrations as 3rd order (3 integrations within 50 kb, 
with integration in WDR74 among others) and 9 integra-
tions as 2nd order (2 integrations within 30 kb, with inte-
gration in DENND1B). Overall, these analyses confirmed 
previous observations that LV integrations are random 
showing a non-biased integration profile not matching a 
known biased integration sequences assigned for gamma-
retroviral genotoxicity such as LMO2 [34]. Long-term 
cultures (30  days) of research-grade SmyleDCpp65 (pro-
duced with IDLV or ICLV without the cryopreservation 
step) were longitudinally harvested on days 10, 20 and 30, 
showing progressive reductions of LV copies (Additional 
File 3: Figure S3A). Pooling these time-points for each 
vector type, we observed that most of the ICLV and IDLV 
integrations combined were in gene ±10 kb outside genes 
(Additional File 3: Figure S3B-D). Analyses of the cultures 
maintained for up to 30 days showed also a consistent ran-
dom integration in genes and polyclonality (Additional File 
3: Figure S3C-D). Integration sites that showed up more 
Figure 5 Characterization of SmyleDCpp65 after in vitro culture for 
5 or 7 days without exogenous cytokines. a Average frequency of 
activated DCs co-expressing HLA-DR/CD80. b Average frequency of 
pp65+ cells detected after intracellular staining and FACS. c Concen-
tration of transgenic cytokines GM-CSF and IFN-α in cell supernatants 
harvested AT, and on days 5 and 7 after thaw (pg/106 cells/mL). d 
Concentration of endogenously up-regulated MCP-1 and IL-8 in cell 
supernatants harvested AT, and on days 5 and 7 after thaw (pg/106 
cells/mL). Data represent the combined data obtained for three inde-
pendent SmyleDCpp65 production runs, two independent analyses 
for GMP1 and three independent analyses for GMP2 and GMP3 (in 
total 8 analyses). Bar graphs indicate mean and error bars indicate 
mean ± SEM. *p < 0.05, **p < 0.01, ****p < 0.0001.
Table 2 Panels for flow cytometry characterization of SmyleDCpp65
Markers used in the characterization of SmyleDCpp65 after thawing and in vitro culture.
Panel I markers and fluorochromes used for detection of surface molecules in viable, non-permeabilized cells, Panel II markers and fluorochromes used for detection of 
surface molecules and pp65 in permeabilized cells.
Viability Pan maker Dendritic cell Activated dendritic cell Cell impurities Intracellular detection 
of pp65 antigen
Panel I SSC & 7AAD– CD45 (KromeOrange) CD14 (APC 750)
CD11c bright (PC7)
HLA-DR (Pacific Blue)/CD86 (PE)
HLA-DR (Pacific Blue)/CD80 (APC)
CD3 & CD19 
(APC700)
n.a.
Panel II n.a. CD45 (KromeOrange) CD14 (APC750)
CD11c bright (PC7)
n.a. CD56 (PC5.5) Anti-pp65 Ab plus sec-
ondary Ab (FITC)
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Figure 6 Analyses of IDLV genomic integrations in SmyleDCpp65. Cells from different production batches (RG-ICLV, RG-IDLV, GMP2 and GMP3) 
were thawed and cultured for 7 days without exogenous addition of cytokines. Total DNA (tDNA) was extracted from the cells for q-PCR or for 
LAM-PCR followed by high throughput integration analyses of LV sequences. a Reference analyses of pp65+ cells detected by FACS for each cell 
product. b Analyses of number of vector copies/cell performed by q-PCR (amplification of WPRE sequences). c Total matched sequences and 
unique integration sites (IS) analyses performed after LAM-PCR (LV sequences amplified with LTR primers) of the tDNA followed by NGS. Fold reduc-
tion from the total matched sequences to IS is indicated. d Frequency of IDLV integrations per chromosome, showing correlation with chromosome 
size. e Distribution of IDLV integrations upstream of transcription start sites (TSS arrow) or within genes. f Ten most pre-dominant clones detected in 
 SmyleDCpp65 (RG-ICLV, RG-IDLV and GMP batches 2 and 3). Colored columns represent retrieval frequency as percentage of total sequences. Larger 
colored bars represent higher frequencies of integration sites clustering in the proximity of that gene. Lower panel Ranking of the 10 most pre-
dominant clones with their corresponding color code and gene ID. Red arrows indicate frequent insertion sites observed in DENND1B and WDR74 
for GMP2. g Common Integration Site (CIS) statistical analyses performed for RG-IDLV and GMP2 and GMP3 batches combined. Red arrows indicate 
recurrent insertion sites observed in the analyses (LIF2, MDM4, WDR74, DENND1B).
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than once in these analyses were WD Repeat-Containing 
Protein 74 (WDR74), ZNF37A, SEL1L, ILF2, but these 
genes are not known as proto-oncogenic. Notwithstand-
ing, a common insertion of IDLV in the analyses of GMP 
batches were observed in WDR74 genes (Figure 6f, g), but 
insertional mutagenesis involved with the human locus was 
not described (NCBI Gene ID: 54663, updated on 17-Mar-
2015). Furthermore, since monocytes and DCs are mostly 
post-mitotic and non-replicating cells, and it is unlikely that 
a biased integration pattern could predispose to insertional 
mutagenesis and genotoxic effects.
Stimulation of autologous T cells with SmyleDCpp65 
in vitro
Ultimately, in order to demonstrate that SmyleDCpp65 
produced under GMP-compliant conditions were func-
tional in stimulating T cells, SmyleDCpp65 produced 
from the three donors were thawed, cultured for 7  days 
and used to stimulate autologous selected CD3+ T cells 
(Figure  7a). The donors used for these studies were all 
HCMV sero-positive and thus contained memory T cells 
reactive against pp65 epitopes. Non-stimulated T cells 
and cells pulsed with a pp65 peptide mix were included as 
experimental parameters. RG SmyleDC and SmyleDCpp65 
produced with CD14+ cells from the same donor were 
used as positive controls. 16 h after stimulation, intracel-
lular staining of IFN-γ and flow cytometry analyses were 
performed (Figure  7b, representative example). T cells 
stimulated with SmyleDCpp65 produced as GMP resulted 
in significant increases in frequencies of IFN-γ producing 
CD8+ T cells (SmyleDCpp65: 9.8%; versus unstimulated, 
p < 0.05) and CD4+ T cells (SmyleDCpp65: 7.5%; versus 
unstimulated p  <  0.05) (Figure  7d). The T cell stimula-
tion was modestly higher for SmyleDCpp65 (GMP or RG) 
than for SmyleDC (which can still activate T cells home-
ostatically, but lack the antigen). Under these assay con-
ditions, the pp65 peptide mix loading on the T cells did 
not stimulate IFN-γ production in CD4+ or CD8+ T cells 
above the non-stimulated T cell control group. Therefore, 
these assays confirmed the functionality of GMP-grade 
SmyleDCpp65 to stimulate T cells in vitro.
Conclusion
For future clinical developments of DCs to be used in 
conjunction with HSCT, novel enabling technologies for 
more potent and viable cell products, easy production 
and cryopreservation and well-defined specifications for 
quality control are needed. In order to fulfill these pre-
requisites, here we advanced towards clinical develop-
ment of SmyleDCpp65 under GMP-compliant conditions. 
SmyleDCpp65 can be genetically induced ex  vivo, self-
differentiate in  vivo, are longer lived and produce com-
bined antigenic effects for immune stimulation (cytokines, 
antigen, donor-matched MHC). GM-CSF and IFN-α 
are cytokines broadly used as generic drugs and biologic 
response modifiers against leukemia, and their safety and 
pharmacology have been extensively characterized. The 
pp65 HCMV antigen was evaluated in different types of 
vaccines in clinical trials and demonstrated potent T cell 
stimulatory properties not associated with immune toxic-
ity [5]. In addition, pp65 is abundantly expressed early and 
late after HCMV infection, making it an appropriate anti-
genic target for CTLs. Proof-of-concept pharm-tox studies 
of SmyleDCpp65 in humanized mouse models of HSCT 
demonstrated accelerated immune reconstitution along 
with immunological potency and safety [22, 23]. In follow-
up to these previous in vivo findings, the most important 
features of this current work are:
1. The feasibility to produce IDLV under GMP-compliant 
conditions: Our methods described here delineated 
the clinical grade up-scaling, standardized produc-
tion, cryopreservation and QC for future clinical trials. 
Up-scaling the production of the IDLV and cell trans-
duction were readily reproducible when performed by 
a CMO at GMP level. Our results demonstrated that 
production of IDLV with GMP-compatible methods 
was quite comparable to what has been reported for 
production of ICLV under GMP [35, 36]. The down-
stream processing of the vector did not alter the infec-
tivity or the biological activity of the IDLV to repro-
gram monocytes. Currently, the most limiting factor 
for generation of the SmyleDCpp65 is the high costs of 
IDLV produced under GMP. New technologies driven 
by market competition (such as packaging cell lines 
and optimized up and down-stream processes) can 
potentially reduce the price of lentiviral production.
2. Use of fresh leukapheresis samples for SmyleDCpp65 
manufacturing under GMP-compliant conditions and 
subsequent cryopreservation: With a standardized and 
simplified 3-day SmyleDCpp65 production method, 
approximately half of the transduced monocytes were 
recovered after 28  h of ex  vivo manipulation. For three 
independent runs, we recovered 40, 46 and 82% of the 
monocytes used for transduction, which for developmen-
tal runs is a satisfactory result (Table 1). Thawing of the 
cells resulted in 30, 58 and 87% of viable cells, indicating 
that the cell handling procedures were technically continu-
ously improved during these three feasibility runs (Table 1). 
Our protocol was established using 1.5 × 108 monocytes. 
After transduction, freezing and thawing, we recovered 
approximately 8 × 107 viable cells. This is a realistic num-
ber for QC testing and use in patients (the target clinical 
dose will be 1 × 106 viable cells for immunization). Non-
mobilized donor-derived monocytes are not the limiting 
factor for SmyleDCpp65 production, since after leuka-
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Figure 7 Characterization of SmyleDCpp65 potency by T cell stimulation in vitro. A 16 h IFN-γ catch assay based on flow cytometry analysis was 
used to evaluate whether SmyleDCpp65 produced under GMP-like compliant conditions (harvested on day 7 after thawing) could activate autolo-
gous CD3+ T cells (n = 3). No antigen (no stimulation) and stimulation with a pp65 peptide mix were used as controls. a Schematic representation 
of T cell stimulation assays performed with SmyleDC or SmyleDCpp65 (research grade, RG) or with cognate SmyleDCpp65 (GMP1, GMP2, GMP3). b 
Representative example showing gating and analyses of CD8+ and CD4+ T cells producing IFN-γ after different stimulations. c Bar graph showing 
the frequencies of CD8+ T cells and d CD4+ T cells producing IFN-γ. Results are indicative of three independent experiments. Bars indicate mean 
and error bars indicate mean ± SEM. **p < 0.05.
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pheresis, we can select approximately 1 × 109 monocytes. 
Incidentally, SmyleDCpp65 could also be produced with 
a fraction (10–15%) of the mobilized stem cell apheresis, 
such that only one apheresis would be needed. This way, 
the short time needed to complete production and quality 
control of SmyleDCpp65 would facilitate this cell therapy 
to be available for administration shortly after HSCT.
3. Detailed quality control for identity and characteriza-
tion: For preclinical quality assurance, we developed the 
specification of the parameters for QC of cryopreserved/
thawed SmyleDCpp65. Inter and intra-experimental 
variations detected for the three pilot SmyleDCpp65 
lots after thaw were small regarding purity of the 
monocytes recovered. Non-clinical characterization 
of cultured SmyleDCpp65 using multicolor immu-
nophenotypic panels (Table  2) showed remarkable 
reproducibility for viability and identity parameters on 
day 7 after in vitro culture (Table 1). An in vitro 16 h 
co-culture system followed by an IFN-γ catch assay 
measured by flow cytometry showed potency of GMP-
grade SmyleDCpp65 to stimulate autologous CD4+ and 
CD8+ T cells.
4. Detailed analysis of the lentiviral vector integration: 
LVs have been shown to be safe in many gene therapy 
clinical trials for gene replacement in HSC [35–39] 
and have been vastly explored for transduction of 
mouse and human DCs in  vitro [15]. A concern for 
LV-based gene transfer is insertional mutagenesis in 
progenitor myeloid cells. It was shown previously that 
HIV DNA integration in macrophages was favored 
in active transcription units [40]. LV integration pro-
files differed between human and rodent post-mitotic 
tissues [41], and therefore these analyses cannot be 
generalized, but analyzed on a case-by-case man-
ner. SmyleDCpp65 are post-mitotic cells and do not 
replicate, enabling IDLV copies to be maintained 
also as episomal or residual integrated copies. Analy-
ses of residual IDLV integration sites in GMP-grade 
SmyleDCpp65 showed a non-modal distribution 
upstream and downstream of transcription start sites. 
Surprisingly, research-grade SmyleDCpp65 gener-
ated with IDLV showed a more pronounced presence 
of vector integrations in a region of 5 kb upstream of 
transcription start site. We hypothesize that the puri-
fied IDLV preparation (i.e. free from empty viral par-
ticles containing p24) favored a random integration 
pattern, whereas non-purified particles could poten-
tially tether to open chromatin at promoter/enhancer 
regions. For subsequent studies with a larger vector 
lot, we plan to assess the risk of generating replication 
competent lentivirus (RCL) as this is a required regu-
latory step for QC [42].
In summary, these results opens perspectives for the 
broad usage of this individualized cell vaccine therapy 
towards clinical trials to improve immune reconstitution 
and protection against HCMV after HSCT. This will be a 
first-in-man evaluation of an advanced therapy-medicinal 
product (ATMP) in an interventional, multicenter, prospec-
tive, randomized, open label, dose-escalating study assess-
ing the safety, maximum tolerated dose and feasibility. The 
Phase I trial will include patients with AML, myelodysplas-
tic syndrome or multiple myeloma transplant-recipients in 
remission at high risk of HCMV reactivation [seropositive 
recipients (R+) receiving HLA-matched stem cells from 
seronegative donors (D−)]. The primary objective will 
be to test the hypothesis that SmyleDCpp65 immuniza-
tions are safe, i.e. will not lead to an increase in incidence 
of acute GVHD, death, infections or occurrence of RCL. 
The secondary objective will be to test the hypothesis that 
SmyleDCpp65 immunizations will stimulate anti-HCMV 
immune responses and earlier quantitative and qualitative 
T and B cell reconstitution after transplantation.
Additional files
Additional file 1:  Figure S1. Feasibility of cryopreservation. (A) 
Tricistronic IDLV encoding for hGM-CSF, hIFN-α and CMV-pp65 protein 
used to generate SmyleDCpp65. (B) Scheme of SmyleDCpp65 genera-
tion. Monocytes were isolated by MACS selection, pre-conditioned with 
cytokines for 8 h, and transduced with IDLV-G2α2pp65 for 16 h. After 
transduction, cells were harvested and cryopreserved at 2x106 cells/
mL/vial. Cells were analyzed immediately after thaw (AT) or cultured in 
medium without exogenous cytokines for 7 days. (C) Viability (7AADneg) 
and identity (CD14 + expression level) of cell product (AT). (D) Total IDLV 
copy numbers detected by RT-q-PCR in the transduced cell groups AT and 
after 7 days in culture. (E) pp65 expression in SmyleDCpp65 (CD14neg, 
CD11cbright) after 7 days of in vitro culture. (F) Viability, down regulation 
of monocyte marker (CD14), identity (CD11cbright and HLA-DR) and 
functional markers (CD86 and CD80) expressed in SmyleDCpp65 7 days 
after in vitro culture.
Additional file 2: Figure S2. Cell line control used in the characteriza-
tion of pp65 expression in SmyleDCpp65 (GMP-like). (A) KA2 cells and KA2 
expressing pp65 (KA2/pp65) were used as negative and positive controls 
respectively for the qualitative determination of intracellular pp65 expres-
sion in SmyleDCpp65.
Additional file 3: Figure S3. Analyses of the lentiviral integration 
sites. RG tricistronic vector (both as integrase competent and integrase 
defective; MOI of 5) were used to transduce monocytes for generation of 
SmyleDCpp65. The cells were maintained in vitro for up to 30 days. The 
clonal contribution of the genetically modified monocytes was monitored 
with a high-throughput IS analysis. (A) Number of vector copies detected 
by RT-q-PCR. (B) Integration pattern of ICLV and IDLV in SmyleDCpp65 
in gene versus in gene ± 10 kb. (C) Integration site frequency distribu-
tion of ICLV and IDLV in SmyleDCpp65 upstream and in genes. (D) 10 
Most predominant clones for ICLV and IDLV. Colored columns represent 
retrieval frequency as percentage of total sequences in SmyleDCpp65 at 
sequential time points of analyses. Larger colored bars represent higher 
frequencies of integration sites clustering in the proximity of that gene. 
Lower panel indicate ranking of the 10 most pre-dominant clones with 
their corresponding color code and gene ID at sequential time points of 
analyses. Arrows (red) indicate recurrent insertion sites observed in the 
analyses.
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